On 6 October, Egypt's Ministry of Health announced the successful registration of a new compound called Aeon. The new compound, which is a combination of three drugs, is designed to treat patients suffering from severe respiratory illnesses, including COVID-19.

The three drugs included in the new compound are hydroxychloroquine, azithromycin, and zinc sulfate. Hydroxychloroquine is an anti-malaria drug that has been widely used to treat COVID-19 patients, while azithromycin is an antibiotic used to treat bacterial infections. Zinc sulfate, on the other hand, is a mineral that has been shown to have antiviral properties and can boost the immune system.

According to the Ministry of Health, Aeon has undergone extensive clinical trials and has been proven to be effective in treating patients with severe respiratory illnesses, including those suffering from COVID-19. The compound has been approved for use in Egypt and is now available in pharmacies across the country.

This new development comes as Egypt continues to battle the COVID-19 pandemic, which has impacted the country's healthcare system and its economy. With over 107,000 confirmed cases and over 6,200 deaths, Egypt is one of the countries hardest hit by the pandemic in the Middle East.

The development of Aeon is seen as a significant step forward in the fight against COVID-19, as it provides clinicians with a new treatment option for patients with severe respiratory illnesses. The Ministry of Health hopes that the new compound will help reduce the number of hospitalizations and deaths related to COVID-19 and other respiratory illnesses in Egypt.

In conclusion, the successful registration of Aeon is a significant development for Egypt's healthcare system and its fight against COVID-19. The new compound provides clinicians with an effective treatment option for patients suffering from severe respiratory illnesses, and it is hoped that it will help reduce the country's healthcare burden caused by the pandemic.